AUA 2022: Implementation of Germline Testing in Prostate Cancer
AUA 2022 implementation of germline testing in prostate cancer, role of germline testing in prostate cancer and clinical implications,
Related Articles
APCCC 2024: Debate: How to Best Manage a Fit Patient with High-Risk Localised and Locally Advanced Prostate Cancer? Surgery as Radical Local Treatment (As Part of a Multimodality Approach)
APCCC 2024, Advanced Prostate Cancer, radical prostatectomy, pelvic lymph node dissection, cN1 disease, Extended pelvic lymph node dissection, RAVES trial, RADICALS-RT trial, GETUG 17 trial,…
APCCC 2024: Radiation Therapy Schedules and Fields for High-Risk and Locally Advanced Prostate Cancer
APCCC 2024, prostate cancer, Radiation Therapy Schedules for prostate cancer, Locally Advanced Prostate Cancer, GETUG-AFU 18 trial, dose-escalated external beam radiotherapy, ultrahypofractionation, ultrahypofractionation via stereotactic…
APCCC 2024: Should the Primary Be Treated in Synchronous High-Volume mHSPC
APCCC 2024 management of metastatic hormone sensitive prostate cancer (mHSPC), synchronous high-volume mHSPC, HORRAD trial, de novo mHSPC, STAMPEDE Arm H, STOPCAP collaboration.
APCCC 2024: In Which Patients with Synchronous Low-Volume mHSPC Do You Recommend “Total Therapy”?
APCCC 2024 metastatic hormone sensitive prostate cancer (mHSPC), patients with mHSPC that should receive “total therapy”, External beam radiation, abiraterone, enzalutamide, apalutamide, darolutamide.
APCCC 2024: Synchronous Low-volume mHSPC – In Which Patients Do You Recommend Combination Systemic Therapy Plus Local Treatment of the Primary and in Which Patients is ADT Alone Plus Radiotherapy Enough?
APCCC 2024 how to manage patients with synchronous low-volume mHSPC, combination systemic therapy plus local treatment of the primary for synchronous low-volume mHSPC, ADT alone…
APCCC 2024: Introduction to mHSPC – What Are Relevant Prognostic/Predictive Factors for the Management of Patients?
APCCC 2024 prognostic factors for the management of patients with metastatic hormone-sensitive prostate cancer (mHSPC), predictive factors for the management of patients with mHSPC
The Adrenal Permissive HSD3B1 Allele: A Decade-Long Journey from Initial Discovery to Proven Clinical Significance in Prostate Cancer – Nima Sharifi
Alicia Morgans and Nima Sharifi discuss the role of the HSD3B1 gene and its variants in prostate cancer. Dr. Sharifi explains that the adrenal permissive…
APCCC 2024: In Patients with BCR and Positive Lesion(s) in the Pelvis – Stereotactic or Whole Pelvis Radiotherapy?
APCCC 2024 treatment for biochemical recurrence/PSA persistence, stereotactic or whole pelvis radiotherapy for patients with biochemical recurrence, APCCC key questions.
The Role of Gene Therapy in Enhancing Bladder Cancer Patient Outcomes – Mark Tyson
Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data…
APCCC 2024: How to Select Patients with Biochemical Relapse in Whom Salvage Radiation Therapy Can Be Postponed?
APCCC 2024, Biochemical Relapse, Salvage Radiation Therapy, androgen deprivation therapy (ADT), biochemical recurrence after radical prostatectomy, Oncotype DX, Prolaris, ProMark, Decipher genomic classifier score, utilization…